Management ChangeAug 4, 2026, 07:07 AM
iBio Appoints Molly Carr, M.D., as Chief Medical Officer
AI Summary
iBio, Inc. announced the appointment of Molly Carr, M.D., as its new Chief Medical Officer. Dr. Carr brings over 30 years of experience in endocrinology and metabolic disease, including a senior role at Eli Lilly and Company, where she oversaw their insulin portfolio and clinical development. In her new role, she will lead iBio's global clinical strategy, medical affairs, and regulatory initiatives as the company advances its cardiometabolic pipeline. Concurrently, iBio granted Dr. Carr options to purchase 430,000 shares of common stock at an exercise price of $1.40 per share, vesting over four years.
Key Highlights
- iBio appointed Molly Carr, M.D., as Chief Medical Officer.
- Dr. Carr brings over 30 years of clinical, academic, and biopharmaceutical experience.
- She previously served as Clinical Head and Associate Vice President of Lilly's Insulin and Glucagon Franchise.
- Dr. Carr will lead iBio's global clinical strategy, medical affairs, and regulatory initiatives.
- iBio granted Dr. Carr options to purchase 430,000 shares of common stock as an inducement award.
- The options have an exercise price of $1.40 per share, equal to the closing price on July 31, 2026.
- The options vest 25% on the one-year anniversary, with an additional 6.25% vesting every three months thereafter.
Price Impact
More from IBIO